View abstract

Cet abstract a été assigné à session BOG-SBO 1 Medische retina/ Rétine médicale
TitreLong-term Outcome of ocular Behcet Disease
Abstract Nr.A1018
ButIn the last 2 decades new immunosuppressive drugs have been introduced for treatment of Ocular Adamantiades- Behcet Disease (ABD).
Although short term prospective studies have proven benefit of these drugs, few comparative studies or long-term studies have been carried out.
Méthodes51 Consenting ABD patients who visited the uveitis clinic in the first 3 months of 2004 with a follow-up > 3 years were included.
Follow-up was divided in 1 month periods and the relation treatment vs. disease control and VA was studied.
In order to compare current with past prognosis, patients were divided in 3 groups of 17 patients according to date of 1st presentation: group A 1966-88 ; B 1989-95 ; C 1995-2001
RésultatsMean follow up was 12 years. A total of 13749 1 month periods were studied. Visual prognosis and disease control at each time (calculated since onset) during follow up was best in group C compared to group B and A (p = 0.00). Treatment was compared with steroid monotherapy. During periods of active disease, combination steroids-Methotrexate (MTX) was best. Steroid-Cyclosporine A (CSA) and Steroid-Chlorambucil were also better than steroids alone. No benefit could be detected using steroids-Mycophenolate Mofetil (MMF) or steroid-azathioprine.
In periods of quiescent disease, superior control and visual outcome was achieved with combination of steroids with MTX, CSA or MMF.
ConclusionNew therapies for ocular Behcet disease have been introduced over the last decades and have improved prognosis significantly. Surprisingly, in our series the combination of Methotrexate and steroids seemed the most successful bi-therapy.
Author 1
NomMISSOTTEN
InitialesT
InstitutMoorfields Eye Hospital
VilleLondon
Author 2
NomLAU
InitialesC
InstitutMoorfields Eye Hospital
VilleLondon
Author 3
NomLIGHTMAN
InitialesS
InstitutMoorfields Eye Hospital
VilleLondon
top ^